Today, 21st March 2019, an Extraordinary General Meeting of SynAct Pharma AB was held. The following is a summary of the decisions taken. Decisions were taken with the required majority.
Election of new members of the Board of Directors
The meeting elected Terje Kalland and John Haurum to the Board of Directors. It was also noted that existing members of the Board of Directors except Lars Adlersson and Charlotte Edenius, who have asked to stand down, remain on the board.
Amendment of the Articles of Association
The meeting resolved to amend the Articles of Association as follows:
| Old wording | New wording |
| § 1 Company The company’s business is Synact Pharma AB. The company is public (publ). | § 1 Company name The company’s business name is Synact Pharma AB. The company is public (publ). |
| § 4 Share capital Share capital shall be at least SEK 600,000 and not more than SEK 2,400,000. | § 4 Share capital Share capital shall be at least SEK 1,800,000 and not more than SEK 7,200,000. |
| § 5 Number of shares The number of shares shall be at least 4,800,000 and not more than 19,200,000. | § 5 Number of shares The number of shares shall be at least 14,400,000 and not more than 57,600,000. |
| § 8 Notice of General Meetings Notice of General Meetings shall always be made through advertising in periodicals and domestic newspapers and on the company’s website. That notice has been given must be advertised in Svenska Dagbladet. If the Svenska Dagbladet were to cease publishing, advertising should instead take place via Dagens Industri. In addition to the place where the Board has its seat, the General Meetings may be held in Stockholm Municipality, Stockholm County. | § 8 Notice of General Meetings Notice of General Meetings shall always be made through advertising in periodicals and domestic newspapers and on the company’s website. That notice has been given must be advertised in Svenska Dagbladet. If the Svenska Dagbladet were to cease publishing, advertising should instead take place via Dagens Industri. In addition to the place where the Board has its seat, the General Meetings may be held in Stockholm municipality, Stockholm county or in Malmo municipality, Skåne County. |
The meeting further authorised the Board, or the Board’s appointee, to make any minor adjustments to the Annual General Meeting’s decisions that may prove necessary in the registration of decisions.
Lund, March 2019
SynAct Pharma AB (publ)
BOARD OF DIRECTORS
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Telephone: +45 40 15 66 69
E-mail: tj@synactpharma.com